In a case study of its so-called “drug of the year,” Trinity noted that argenx was able to successfully secure market-leader status for Vyvgart soon after its launch thanks to its “safer ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

These drugs work by blocking FcRn and impairing ... its core portfolio with the help of collaborative partners. The molecule in Vyvgart originated from a collaboration with UT Southwestern Medical ...

argenx SE (NASDAQ:ARGX) reported Q4 2024 results and provided a pipeline update today, but without major surprises since the company provided Vyvgart net sales and a corporate update ahead of the ...

Immunovant's IMVT-1402 reduced IgG by 74% with weekly dosing, while Argenx's approved drug, Vyvgart, lowered IgG ... Notably, Biohaven's drug is a small molecule. This makes it easier to ...

UCB also notes that unlike monoclonal antibody C5 inhibitors Zilbrysq is a smaller peptide molecule ... for Vyvgart Hytrulo (efgartigimod alfa), a subcutaneous FcRn blocker, in June. That drug ...

of $737 million in fourth quarter and $2.2 billion in full year of 2024 Multiple VYVGART regulatory submissions completed for gMG, including: Ministry of Food and Drug Safety approved VYVGART (IV ...